Innovent Biologics Inc

01801

Company Profile

  • Business description

    Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

  • Contact

    168 Dongping Street
    Suzhou Industrial Park
    Jiangsu Province
    Suzhou215123
    CHN

    T: +86 51269566088

    https://www.innoventbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    5,659

Stocks News & Analysis

stocks

Our three most overvalued ASX shares

These three companies are trading at a significant premium to our fair value.
stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks

Our only 5-star wide moat ASX share

A difficult year but better times ahead.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,140.5011.000.12%
CAC 407,656.1042.82-0.56%
DAX 4023,625.66144.67-0.61%
Dow JONES (US)45,316.53304.76-0.67%
FTSE 1009,204.9811.89-0.13%
HKSE25,417.98359.471.43%
NASDAQ21,621.7185.98-0.40%
Nikkei 22543,018.75438.481.03%
NZX 50 Index13,190.3233.21-0.25%
S&P 5006,464.5837.50-0.58%
S&P/ASX 2008,871.208.600.10%
SSE Composite Index3,812.5146.641.24%

Market Movers